Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 3Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Congenital Abnormalities 1

Interventions

Cytarabine 12Peripheral Blood Stem Cell Transplantation 10fludarabine phosphate 7Cyclosporine 7Mycophenolic Acid 6Busulfan 6Methotrexate 5Melphalan 4Idarubicin 4Filgrastim 4Etoposide 4Clofarabine 4aldesleukin 3Whole-Body Irradiation 3Tacrolimus 3Radiotherapy 3Mitoxantrone 3Flow Cytometry 3Daunorubicin 3Cyclophosphamide 3Antilymphocyte Serum 3Transplantation 2Radiotherapy, Intensity-Modulated 2Interleukin-2 2Granulocyte Colony-Stimulating Factor 2Cytogenetic Analysis 2Bortezomib 2Alemtuzumab 2tipifarnib 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Congenital Abnormalities × laromustine × Clear all
NCT00840684 2011-05-13

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
135 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡